LANXESS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

LANXESS şirketinin toplam hissedar öz sermayesi €4.4B ve toplam borcu €3.0B olup, bu da borç-öz sermaye oranını 68.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €9.4B ve €5.1B dir. LANXESS 'in FAVÖK'ü €1,000.0K faiz karşılama oranı 0 dur. Şirketin €423.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

68.8%

Borç/özkaynak oranı

€3.01b

Borç

Faiz karşılama oranı	0.03x
Nakit	€423.00m
Eşitlik	€4.38b
Toplam yükümlülükler	€5.07b
Toplam varlıklar	€9.45b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0H7I 'nin kısa vadeli varlıkları ( €3.3B ) kısa vadeli yükümlülüklerini ( €1.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 0H7I 'un kısa vadeli varlıkları ( €3.3B ) uzun vadeli yükümlülüklerini ( €3.4B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0H7I 'nin net borç/öz sermaye oranı ( 59.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 0H7I 'nin borç/öz sermaye oranı son 5 yılda 102.7% seviyesinden 68.8% seviyesine düştü.

Borç Kapsamı: 0H7I 'nin borcu işletme nakit akışı ( 12.5% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 0H7I 'in borcuna ilişkin faiz ödemeleri EBIT ( 0 x kapsam) tarafından iyi karşılanmıyor.

LANXESS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: €0.01 (vs €1.52 loss in 3Q 2023)

UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million.

Second quarter 2024 earnings released: €0.19 loss per share (vs €1.68 loss in 2Q 2023)

LANXESS Aktiengesellschaft Announces Executive Changes

Upcoming dividend of €0.10 per share

First quarter 2024 earnings released: €1.13 loss per share (vs €0.12 profit in 1Q 2023)

Dividend reduced to €0.10

Full year 2023 earnings released: €9.76 loss per share (vs €2.13 profit in FY 2022)

Lanxess Reportedly Seeks to Sell Polyurethane Ops

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: €1.52 loss per share (vs €0.97 profit in 3Q 2022)

LANXESS Aktiengesellschaft Proposes Dividend for the Fiscal Year 2023

LANXESS Aktiengesellschaft to Report Q1, 2024 Results on May 08, 2024

LANXESS Aktiengesellschaft(XTRA:LXS) dropped from FTSE All-World Index (USD)

New major risk - Revenue and earnings growth

New major risk - Dividend sustainability

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released

Now 32% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of €1.05 per share at 3.0% yield

Now 20% undervalued after recent price drop

First quarter 2023 earnings released: EPS: €0.12 (vs €0.76 in 1Q 2022)

Now 23% undervalued after recent price drop

Full year 2022 earnings released: EPS: €2.13 (vs €2.54 in FY 2021)

Now 20% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €0.97 (vs €0.46 in 3Q 2021)

Second quarter 2022 earnings released: EPS: €0.56 (vs €0.54 in 2Q 2021)

LANXESS Aktiengesellschaft (XTRA:LXS) completed the acquisition of Microbial Control business unit of International Flavors & Fragrances Inc. (NYSE:IFF).

Investor sentiment deteriorated over the past week

LANXESS Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Advent International Corporation and LANXESS Aktiengesellschaft (XTRA:LXS) agreed to acquire Engineering Materials business of Royal DSM from Koninklijke DSM N.V. (ENXTAM:DSM) for €3.9 billion.

Investor sentiment improved over the past week

Upcoming dividend of €1.05 per share

First quarter 2022 earnings released: EPS: €1.13 (vs €0.73 in 1Q 2021)

LANXESS Aktiengesellschaft Provides Financial Guidance for the First Quarter of 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

LANXESS Announces Executive Changes

Lanxess Reportedly Teams Up with Advent to Bid for DSM's Materials Ops

Second quarter 2021 earnings released: EPS €0.89 (vs €9.32 in 2Q 2020)

TFL Ledertechnik GmbH completed the acquisition of organic leather chemicals business from LANXESS Aktiengesellschaft (XTRA:LXS).

First quarter 2021 earnings released

Upcoming dividend of €1.00 per share

Full year 2020 earnings released: EPS €10.30 (vs €2.89 in FY 2019)

Revenue beats expectations

New 90-day high: €66.53

LANXESS Aktiengesellschaft (XTRA:LXS) completed the acquisition of Intace SAS.

Lanxess Announces Executive Changes

LANXESS Aktiengesellschaft (XTRA:LXS) signed an agreement to acquire Intace SAS.

New 90-day high: €64.13

LANXESS Starts Talks to Acquire Theseo

Suez SA (ENXTPA:SEV) completed the acquisition of reverse osmosis membranes business from LANXESS Aktiengesellschaft (XTRA:LXS).

New 90-day high: €63.98

Lanxess Reportedly to Bid for Emerald Kalama Chemical

New 90-day high: €60.82

New 90-day high: €53.32

Third quarter 2020 earnings released: EPS €0.30

Revenue misses expectations

New 90-day low: €43.46

LANXESS Aktiengesellschaft to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high - €51.78

LANXESS Aktiengesellschaft to Report Q3, 2021 Results on Nov 04, 2021

Earnings released

TFL Ledertechnik GmbH signed an agreement to acquire organic leather chemicals business from LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €200 million.

Funds managed by Macquarie Infrastructure and Real Assets completed the acquisition of remaining 40% stake in Currenta GmbH & Co. OHG from LANXESS Aktiengesellschaft (XTRA:LXS) for €780 million.

Suez SA (ENXTPA:SEV) signed an agreement to purchase reverse osmosis membranes business from LANXESS Aktiengesellschaft (XTRA:LXS).

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin